Anindita Mukerjee
Overview
Explore the profile of Anindita Mukerjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gdowski A, Lampe J, Lin V, Joshi R, Wang Y, Mukerjee A, et al.
ACS Appl Nano Mater
. 2021 Feb;
2(10):6249-6257.
PMID: 33585803
Targeting therapeutic agents to specific organs in the body remains a challenge despite advances in the science of systemic drug delivery. We have engineered a programmable-bioinspired nanoparticle (P-BiNP) delivery system...
2.
Mukerjee A, Ranjan A, Vishwanatha J
J Biomed Nanotechnol
. 2018 Jan;
12(7):1374-92.
PMID: 29336533
A major challenge in pharmaceutical research is effective targeting strategies to their sites of action. Emerging knowledge and the current progress in nanotechnology based delivery systems has opened up exciting...
3.
Pieretti S, Ranjan A, Di Giannuario A, Mukerjee A, Marzoli F, Di Giovannandrea R, et al.
Colloids Surf B Biointerfaces
. 2017 Jul;
158:379-386.
PMID: 28719859
Given the poor bioavailability of curcumin, its antinociceptive effects are produced after chronic intravenous administration of high doses, while poly (d,l-lactide-co-glycolide)-loaded vesicles (PLGA) can improve drug delivery. This paper investigates...
4.
Ranjan A, Mukerjee A, Gdowski A, Helson L, Bouchard A, Majeed M, et al.
J Biomed Nanotechnol
. 2016 Jun;
12(4):679-88.
PMID: 27301194
Non-small-cell lung cancer therapy is a challenge due to poor prognosis and low survival rate. There is an acute need for advanced therapies having higher drug efficacy, low immunogenicity and...
5.
Mukerjee A, Iyidogan P, Castellanos-Gonzalez A, Cisneros J, Czyzyk D, Ranjan A, et al.
Bioorg Med Chem Lett
. 2015 Apr;
25(10):2065-7.
PMID: 25900220
Cryptosporidiosis, a gastrointestinal disease caused by protozoans of the genus Cryptosporidium, is a common cause of diarrheal diseases and often fatal in immunocompromised individuals. Bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) from...
6.
Gdowski A, Ranjan A, Mukerjee A, Vishwanatha J
Int J Mol Sci
. 2015 Feb;
16(2):3990-5.
PMID: 25690029
Treatments utilizing monoclonal antibody therapeutics against intracellular protein-protein interactions in cancer cells have been hampered by several factors, including poor intracellular uptake and rapid lysosomal degradation. Our current work examines...
7.
Gdowski A, Ranjan A, Mukerjee A, Vishwanatha J
Adv Exp Med Biol
. 2014 Mar;
807:33-58.
PMID: 24619617
The ability to detect many cancers at an early stage in its clinical course has the potential to improve patient outcomes in terms of morbidity and mortality. Nanosized components incorporated...
8.
Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation
Ranjan A, Mukerjee A, Helson L, Vishwanatha J
J Nanobiotechnology
. 2013 Dec;
11:40.
PMID: 24330336
Background: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration...
9.
Ranjan A, Mukerjee A, Helson L, Gupta R, Vishwanatha J
Anticancer Res
. 2013 Sep;
33(9):3603-9.
PMID: 24023285
Background: Liposome-based drug delivery has been successful in the past decade, with some formulations being Food and Drug Administration (FDA)-approved and others in clinical trials around the world. The major...
10.
Ranjan A, Mukerjee A, Helson L, Vishwanatha J
J Nanobiotechnology
. 2012 Sep;
10:38.
PMID: 22937885
Background: Nanoparticle based delivery of anticancer drugs have been widely investigated. However, a very important process for Research & Development in any pharmaceutical industry is scaling nanoparticle formulation techniques so...